Angeles Wealth Management LLC Invests $200,000 in Takeda Pharmaceutical Co. $TAK

Angeles Wealth Management LLC purchased a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,950 shares of the company’s stock, valued at approximately $200,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TAK. Farther Finance Advisors LLC boosted its position in shares of Takeda Pharmaceutical by 29.2% during the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after purchasing an additional 1,045 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Takeda Pharmaceutical by 22.6% during the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock worth $105,000 after purchasing an additional 1,296 shares in the last quarter. Fifth Third Bancorp boosted its position in shares of Takeda Pharmaceutical by 85.5% during the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock worth $78,000 after purchasing an additional 2,411 shares in the last quarter. Sagespring Wealth Partners LLC bought a new position in shares of Takeda Pharmaceutical during the first quarter worth $162,000. Finally, Sequoia Financial Advisors LLC boosted its position in shares of Takeda Pharmaceutical by 70.3% during the first quarter. Sequoia Financial Advisors LLC now owns 64,599 shares of the company’s stock worth $961,000 after purchasing an additional 26,656 shares in the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Trading Up 1.2%

Shares of NYSE:TAK opened at $14.05 on Friday. Takeda Pharmaceutical Co. has a 12 month low of $12.80 and a 12 month high of $15.69. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The company’s fifty day simple moving average is $14.81 and its 200 day simple moving average is $14.75. The firm has a market cap of $44.71 billion, a price-to-earnings ratio of 46.83 and a beta of 0.21.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of Takeda Pharmaceutical in a research report on Tuesday, October 14th. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 21st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Takeda Pharmaceutical presently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.